World's first medical networking and resource portal

Articles
Category : General Medicine
Medical Articles
Jul21
RECENT ADVANCES OF MYASTHENIA GRAVIS
INTRODUCTION
‘MG’ the commonest neuromuscular junction (NMJ) disorder caused by Auto antibodies against the Nicotinic AChRs on post synaptic membrane (PSM) and characterized by weakness and fatiguability of voluntary muscles.
• Being very disabling often fatal, a relatively obscure condition is now best characterized and understood autoimmune disorder with greatly improved understanding in pathogenesis/ immunology/ Molecular Biology over last 3 decades.
• The practical mortality rate is ‘o’ with newer advancements.
CLASSIFICATION
Based upon onset of age / Anti Ach R antibodies/severity /etiology.
1. Age of onset:
• Transient Neonatal MG (10-20%). Due to passage of Anti AchR – Abs through placenta to newborn baby. Presents with Hypotonia , Resp.difficulty in 1st few hours of life. Symptoms disappears within 1-3 hours . May require temporary supports , pyridostigmine.
• Adult Autoimmune MG
2. Presence or absence of Anti AChR – Abs :
• Seropositive MG: Commonest acquired autoimmune MG. 85% general MG, 50-60% ocular MG
• Seronegative SNMG (10-20%): No Anti AchR – Abs detectable by RIA, Involve antibodies against one or more components of NMJ (not detectable by current Anti AchR – RIA), One subgroup (40%) of SNMG contains anti MuSK Abs , humoral factors IgG, Non IgG (Possibly IgM) antibodies, which reversibly & indirectly inhibits AchR function.

3. Severity
A. Modified Osserman Scale:
a. Ocular myasthenia
b. Mild generalized - Symptoms sparing oculopharygeal muscles
c. Moderate generalized- Weakness with mild to moderate oropharyngeal symptoms
d. Severe - Disability (generalized) including oropharyngeal/ Respiratory muscles
e. Myasthenic crisis
B. Modified form by American Committee of mg foundation
i. Any ocular weakness (may have weakness of eye closure with all other muscle strength – normal)
ii. Mild weakness other than ocular muscles…  ocular muscle weakness of any severity
IIa – Prominent limb/axial involvement,
IIb – Predominant oropharyngeal / Respiratory involvement
iii. Moderate weakness other than OM, may have ocular weakness
IIIa – Predominant limb/Axial involvement
IIIb – Predominant oropharyngeal /Respiratory involvement
iv. Severe Weakness other than OM, May have ocular weakness
IVa – Predominant limb/Axial involvement
IVb – Predominant oropharyngeal /Respiratory involvement
v. Intubation with or without mechanical ventilation
(Except when patient kept during post operative management)
4. Etiology
a) Acquired autoimmune MG
b) Transient Neonatal MG
c) Drug induced Mg – ‘D Penicillamine’
d) Congenetal Myasthenic syndrome – exacerbated with curare /Aminoglycosides/quinine /procainamide /Ca+2 blocker
NORMAL ANATOMY & PHYSIOLOGY OF NMJ
Role of NMJ:
• Amplification of weak N. impulse to strong – capable of producing muscle contraction
• Components: (a) Presynaptic (b) Synaptic(c) Post Synaptic
Presynaptic :
Arrival of N. impulse

Stimulus – Secretion coupling

Release of 150 – 200 quanta (each with 8000-13000 AChmol)
Exocytosis – help in relasing ACh

Pinocytosis – Recapturing of PSM, vesicles are remade, being repleted with ACh.
• ‘ACh – release sites’ – located opposite to the peaks of folds of PSM where ‘AchR” are clustered in high concentration.
Synaptic Cleft:
Space – 70nm wide, length equal to pre-synaptic membrane, Communicates to extracellular space , No. lateral boundary. Primary cleft: Space separating pre & post synaptic membrane. Secondary cleft: Space between junctional fold of synaptic membrane. ‘AchE’ highly concentrated in secondary cleft . ‘ACh’ released into the space before it acts on ‘AchR’ and hydrolysed by ‘AchE’ to terminate NMT, so that muscle fibre can be stimulated again. ACHE inhibitors increase availability of ‘Achs’ and increases NMT in “MG”
Post synaptic:
Surface of muscle cell membrane, present itself with junctional folds having slender (Stalk) & terminal expansion (Peak). ‘AchRs’ mostly concentrated in ‘Peaks of these folds.
AchReceptor & Its structure
A glycoprotein with five subunits around a central channel. Subunits are : Two ‘’ , one ‘’ , one ‘’ one ‘’/’’. ‘’ subunit is replaced by ‘’ in an immature /denervated muscle. In resting stage ion channels remain closed.
NORMAL PHYSIOLOGY









Once -subunits occupied by ACh slight twisting of AchR like Chineese purse  opening of ion channel  rapid entry of Na+ ions into interior of muscle cells  partial depolarization of PSM at end plate region  generation of Excitatory Post Synaptic Potential (EPSP).
** - When number of opening channels reaches threshold  self propagating action potential triggers muscle contraction.
** - ‘Synaptic Run Down’ (SRD) – progressive decreases in ACh release on repeated Nerve Stimulation (NS).
** ‘Safety Factor’ (SF) – Higher amplitude of End Plate Potential (EPP) than potential required to trigger Muscle Action Potential (MAP).
NMJ abnormality in “MG”:
Reduced SF with normal SRD &#61614; progressive decline in muscle power on Repeated Nerve Stimulation (RNS). Fundamental defect: decreased AchRs at Post Synaptic Membrane (PSM) (<1/3rd) . Flattened & simplified Post Synaptic (PS) folds &#61614; Decreased NMT. Production of small EPP &#61614; Failure in triggering &#61614; Weak muscles contraction
Major post synaptic abnormalities:
Decrease in AChRs causing reduction in PSM length. Shortening of synaptic fold due to destruction of terminal expansion. Widening of synaptic cleft by shortening of junctional folds.
IMMUNOPATHOGENESIS IN MG
Evidence in favor of immunoattack:- ‘AChR- abs’ found in 80-90% patients (Lindstrom et al , 1976). Circulating anti ‘AChR- abs’ found in transient Neonatal MG that declines when patient recovers. Passive transfer of IgG to mice produce similar disease (Vincent & Newson, 1985) Plasmapheresis lowers ‘AchR’ level resulting improvement. IgG abs bind to AchR being localized at the crest of PSM folds (Engel et al, 1979). Experimental model of MG can be produced with purified ‘AchR’
MECHANISM OF DESTRUCTION of ‘AchRs’:
Blockade of the active sites of ‘AchR’. Accelerated turn over with alteration in ‘AchR’ with rapid endocytosis & degradation by muscle cells. Antibody and complement mediated Destruction of Junctional folds of PSM (Engel et al, 1977). Serum AchR concentration does not correlate with severity, rather depends upon. (a) Antibody activity – Accelerated degradation, blocking of AchR ability to bind complements. (b) Difference in NMJ – of different patients / of different muscles of same patient.
Immunopathology & seronegative MG
Circulating Abs not detectable by RIA can destroy AchR in culture system. Produce similar illness when transferred to MICE. Few SNMG patients shows abtibody against MUSK (Muscle Specific Kinase) the protein of anchoring & clustering of AChRs at PSM. Interference in anchoring & clustering impair NMT. Other group of SNMG patients shows undetectable ‘antibodies (abs)’ against other components of NMJ.
Role of T Cells
Thymic ‘T’ cells – more responsive than peripheral blood T cells (Sommer et al, 1990). Thymus contain more ‘B’ cell & produce more abs against ‘AChR’ than control (Scadding et al, 1981). Presence of myeloid cells (Striated /Multinucleated/Muscle like cells) (Vande Velde & Friedman, 1970) having ‘AChR’ on their surface (Kao & Drachman , 1977) surrounded by (CD4+) T cells (Kirchner et al , 1988). Molecular mimicry of myeloid & skeletal muscle AChR & association with immunocompetent cells altogether constitute the important mechanistic hypothesis causing MG.
CLINICAL FEATURES
Presentation: History of cardinal features – ‘weakness & fatiguability’ of muscles on sustained /repeated activity with sudden /gradual onset. Improves after rest. Variation: Diurnal & timely variation. Factors affecting – exertion , hot temperature, infection , emotion, surgery, menstruation, pregnancy, drugs (aminoglycosides, phenytoin). Remission : Rarely complete & permanent. Tendency to long term spontaneous remission & relapse (lasting for weeks). Distribution of weakness (decreased order). Levator palpabrae superioris. Extraocular muscles (initially in 50%, eventually in 90%). Proximal limb muscles (Triceps , deltoid, illospoas). Muscles of facial expression , mastication & speech. Neck extensors. Progression: ocular &#61614; facial &#61614; lower bulbar &#61614; truncal &#61614; limb muscles

SIGNS & SYMPTOMS
Ocular
Presenting symptoms is more than one half of patients. Pupil never involved. Ptosis & diplopia: Initial symptom in 2/3 cases , all develop within 2 years. Fluctuating & shifting in nature. Asymmetric when B/L. Increases with repeated closure & prolonged upward gaze. Due to weakness of levator palpabrae superioris . Not pathognomonic for MG. Worsens after TV watching /Driving /Bright Light
Bulbar
Dysarthria , dysphagia, weak mastication. ‘Hanging jaw sign’, jaw opening is > stronger than closing. Low fading, MUSHY voice – on hasty, laborious , continuous talk, dysphonia (laryngeal weakness).Nasal twang and Nasal timbre (hypernasal speech) (palatal weakness). Nasal regurgitation, poor gag reflex, weak tongue . Difficult swallowing and aspiration of foods. A flurry of weak & ineffective cough.
Facial
Bifacial weakness. Loss of facial expression ‘myasthanic face”. ‘Sleepy’ or ‘sorry face’ pitiable appearance. Horizontal smile – depressed grin (myasthenic snarl). Upper lips elevates transversely in an apparent snarl, smile is limited , showing only the canines as the corners are not drawn up. Difficulty in smoking and whistling. Women complain difficulty in applying lipstick as unable to purse & roll their lips.
Muscles Of Neck
Extensor > flexors. ‘HEAD PTOSIS’ – FLOPPY HEAD SYNDROME, head drops forward in older patients with selective weakness of extensors. Attentive appearance - hand supporting the dropped jaw and falling head with thumb under chin, middle finger curled under bottom lip & the index finger up the check.
Diaphragmatic & intercostals muscles: Isolated respiratory failure, Exertional stridor
Limbs & trunk:
Proximal > distal ( difficulty in rising from chairs , lifting the arms over hand , climbing stairs, combing hairs , walking , running ). Arms> legs, Symmetric involvement.
Deep tendon jerks: Preserved , BRISK in week muscles .
Muscle Wasting : Uncommon except when chronic & untreated
Sensory: Normal.
STAGES OF WEAKNESS: Maximum Weakness In 1st Year In 2/3rd Patients
Active Stage: Fluctuating symptoms over short period – progress to severity
Inactive stage: Fluctuation in strength still occurs (attributable to fatigue /illness), Burnt out stage: Most severily affected muscles become atrophied.

DIAGNOSIS
Firm diagnosis is must as MG requiring thymectomy /long term immuno therapy. To avoid inappropriate treatment, unwanted side effects in patients who do not have the disease. Non pharmacological clinical tests , Pharmacological , serological & electrodiagnostic tests are to be done.
Strategy:
Diagnosis based upon (1) Characteristic history & physical examination (2) Two +ve diagnostic tests (serological & electrodiagnostic)
Diagnostic test must include: Testing for “Serum’ Anti AChR –antibody and RNS study

Physical Examination
Detection of Ptosis : (Ocular examination)
On prolonged upward gaze or repeated closure of eye lid, Test showing ‘seesaw’ phenomenon & Herring’s law of equal innervation. Test for eye lid twich response ‘Cogans Lid Twitch’. Evidence for spontaneous eye lid retraction ‘pesudointernuclear ophthalmoplegia’ in patients of MG. Myasthenic sustained gaze fatigue. Test for ‘orbicularis oculi’ strength. Test for ‘orbicularis oculi’ fatigue ‘peak sign’. Sleep test : no ptosis after few minutes rest. Safe, moderately sensitive & specific way to confirm improvement lasts for 2-5 mins. (Odel et al, 1991).
Ice Test:
Local Cooling: (from 35 – 360 C to 280C)
Decreases decremental response, NM gitter , weakness &#61614; ptosis improves, Positive response in 80% of MG patients.
PHARMACOLOGICAL METHODS:
Tensilon Test
Drug: Edrophonium (10mg)
Action: Inhibits AchE, Prolongs presence of ‘ACh’ in NMJ, increases muscle strength
Time Course: Rapid onset within 30-45 seconds, short acting. Result last for 2 minutes
Procedure: Initially 2mg IV, Observe for 2 minutes – No response – Add 8 mg, Look for weakness of Extra Ocular Muscles (EOM), Impairment of speech, Length of time patient can keep arms forwards in abduction, Fight with 0.6 mg atropine when troublesome
Utility: Useful only in patients with objective , preferable , measurable findings, Sensitivity for MG –relatively low - 60%, Should not be used in dose adjustment of pyridostigmine, False +ve - In LES, localized intracranial mass lesion, ALS (Amyotropic lateral Sclerosis).
Prostigmin Test :
Utility: In diagnosis of MG in patients with diplopia without ptosis, in non-co-operative children where IV tensilon is unsuitable
Procedure: Inject 0.6 mg atropine + 1.5 mg prostigmine &#61614; IM into deltoid
Result :Change in ocular motility & ptosis within 15 seconds, most obvious in 30 seconds,
Dose in Children: 0.04 mg/kg not > 1.5 mg ( total dose ). Negative result does not ruleout the disease
SEROLOGICAL:
a. Anti AChR Antibody Test:
Gold standard diagnostic, highly specific. It is +ve in 80-85% of Gen. MG , 50-60% in ocular MG, 50% in childhood MG, 100% in MG with thymoma.
Procedure : Detection through RIA by ACh – receptor labeled by I 125 or &#61537; Bungarotoxin
Interpretation : High titre does not correlate with severity, Mild disease can have high titre, Decreases Titre (>50%) indicate favorable response to treatment, Negative test does not exclude the disease, False +ve in - ALS, LES (13%), Primary Lung cancer , Older patients (> 70 years) , Neuromyotonia
b. Anti MuSK Antibodies:
+ve in few group in SNMG patients, ‘Abs’ not seen in sera of normal person nor concurrently with Anti-AChR antibodies.
ELECTROPHYSIOLOGICAL DIAGNOSIS
A. RNS (Repeated N. Stimulation):
Most frequently used electro diagnostic (ED) test.
Caution : Withdrawal of AChE medication 6-24 hour before
Muscle choice : Weak muscles or proximal muscle group.
Procedure: Electrical N. stimulation 6-10 times @ 2-3 Hz and recording of Compound Muscle Action Potential (CMAP) with surface electrodes over muscle.
Result: Progressive rapid reduction /Decremental response of ‘CMAP’ > 10-15% from 4th response onwards.
Interpretation: CMAP is normally unchanged or 4th response is slightly smaller than 1st (7%), Significant when decreases > 10%.








Single Fibre Electromyography (SF- EMG):
Most sensitive (95%) in both General and Ocular MG
Principle : Muscle fibres innervated by single axon., Normally activated with consistent latencies, ‘Jitter ‘ the mean inter potential difference between 2 fibres, Increase variability seen in NMJ disorder, Normally < 55&#61549;s. But >100&#61549;s in MG
Interpretation: Abnormal Jitter may not be specific for MG, Also seen in the ALS, LEM , Polymyositis, More specific with large degree Jitter

OTHER DIAGNOSTIC TESTS:
&#61656; CT, MRI, X-ray : Screening of Thymic tumor. Greater yield in > 40 years age.
&#61656; CBC, ESR, TFT, PFT, FBS , Montoux, RA Factor , ANA etc., to screen associated disorders.
OTHER ASSOCIATED AUTOIMMUNE DISORDER:
&#61656; Thyroid disorder (13% of MG)
&#61656; Rheumatoid- Arthritis , SLE, Sarcoidosis , polymyositis, Ulcerative. Collitis, Pemphigus
DIFFERENTIAL DIAGNOSIS
A. Lambert Eaton Syndrome
A presynaptic disorder (Autoantibodies against Ca+2 channels at Motor N. Terminals). Never begins with ocular weakness. Weakness in legs > arms. Depressed & absent reflexes. Shows autonomic changes - dryness, dry mouth , impotence. Increment RNS response
B. Neurasthenia
‘Jerky release’ or ‘Give away weakness’ in muscle testing. C/o tiredness or apathy or decreased muscle power on repeated use.
C. Botulisim
Generalised weakness, Internal & External ophthalmoplegia, Respiratory paralysis. Dilated pupil and incremental response on RNS
D. Hyperthyroidisim : Abnormal ‘TFT’
E. Inherited “MG’: Persistence weakness begins in infancy /early childhood, Muscle biopsy changes don’t explain degree of weakness
F. Intracranial Mass Lesion : Example-Sphenoid ridge meningioma’
Procedures ‘DIPLOPIA” mimicking ‘MG’ illness, Detected by CT/MRI
TREATMENT
&#61656; Modern treatment is highly effective with ‘0’ practical mortality rate (30% before 1958).
Available Tx modalities:
1. AChE inhibitors 2. Plasmapheresis
3. Corticosteroids 4. IV immunoglobulins
5. Immunosupressants 6. Thymectomy
Principle: To minimize the ACh activity at the remaining AChR in the NMJ, To limit/abolish immunological attack on motor end plate.
ACHE INHIBITORS:
Pyridostigmine (MESTINON):Usual 1st line treatment to tie up the progressive MG
Regular Mestinon pills:
• 60mg tabs /(Syp 60mg/5ml)
• Dose: Started with 30 mg , increased gradually, Tailored as per individual requirement, Higher dose –ineffective, more S/E. increases weakness
Time span pills: Sustained release ’90-180mg , used at bedtime , acts over 12 hrs
Advantage: Few Side effects
Disadvantage:
Cholinergic crisis, (symptoms increases with ACh), Effective only in some patients, Muscarinic crisis (Abdominal pain, Diarrhoea) - managed with propanthelene /Diphenoxylate
CORTICOSTEROIDS:
Used for moderate to severe type of MG. Needs prior discussion with patient about S/E & long duration of treatment. Started with low dose 10-20 mg/day to avoid early worsening (48%) on high dose regimen. Increased 5mg every 3rd day upto 60mg. After 3 months higher dose treatment, dose modified to alternate day regimen then gradually tapered. Need months to years to determine the minimal effective dose. Patient may require additional dose on OFF days. Disadvantage: S/E - weight gain/HT/OP/Aseptic necrosis of hip /cataract/ immuno suppression. Needs regular monitoring of BP, FBS, Sr. K+, Bone density (during long term treatment)

IMMUNOSUPRESANTS:
(Azathioprine/cyclophosphamide /cyclosporin /mycofenolate mofetil)
Azathioprine : (Imuran)
1st choice drug because of relative ‘safety’
Dose : 2.5 –3 mg/kg/qd – initial dose
1.5 – 2.5 mg/kg/qd – Maintenance Dose
Indication : Long term immuno suppression , sparing of steroids , decreased S/E.
Monitor: CBC , Platelet, LFT, MCV of Red cells
Advantage: Less S/E
Disadvantage: S/E – Increase risk of malignancy, Decrease RBC, WBC, Platelets. Liver dysfunction, Flulike syndrome (20-30%) (Azathioprine can not be restarted) , Long onset at action and costly
Cyclosporin ‘A’
Dose : Initial 2.5 mg/kg/day, Maintenance – Lowest effective dose
Indication: Long term immunosuppression, When prednisolone cannot be used /ineffective, When rapid response is desired.
Monitoring: RFT, BP, Blood Level (12 hr after previous dose)
Advantage: Short onset of action (1-3 months)
Disadvantage: Serious S/E (Dose related) 35% of patients. Nephrotoxicity , drug interaction with NSAID , Amphotericine -B . Increase risk of malignancy, high cost. Teratogenic , needs serum level monitoring
Mycofenolate mofetil
Dose : 1 gm BD
Indication : Long term , immunosuppression
Advantage: Low risk of malignancy , no major organ toxicity
Disadvantage: High cost , delayed onset of action (6-12 m), limited experience of utilization

PLASMAPHERESIS (PP)
Dose : 5 exchanges (3-4L/Exchange) over 2 weeks period
Indication : Acutely ill patients of MG, Prethymectomy in patients with respiratory /bulbar involvement, Not for long term treatment
Advantage: Very short onset of action (3-10 days), More effective than ‘Human Ig’ in crisis.
Disadvantage: High cost, requires specialized hand and centre, short term benefit, more complication in elderly, side effect > IV Ig
IV. IMMUNOGLOBULIN
Dose : 2 grams /kg (> 2-5 days) (400 mg/kg/day Average)
Indication: Acutely ill MG patients , not for long term treatment
Advantage:
Easy administration , improvement in 70% of patients, widely available , Rare serious S/E, Less S/E than PP (headache, fluid overload, renal shut down , aseptic meningitis)
Disadvantage:
High cost, benefit not well demonstrated, short term benefit, less effective in crisis.
THYMECTOMY
(Removal of source of continued Auto Antigen, B-cells , immunomodulations)
Indications: a. Thymoma b. Gen. MG patients (~ 8 to 55 years)
Approach : Transsternal (standard method, always with thymoma)
Transcervical (performed under direct visualization)
Drawback: Requires Experienced Skill hands
Caution “ ‘Muscle relaxants ‘ should be avoided prior to surgery.
Special Situations
1. Myasthenia & pregnancy :
Myasthenic women : 1/3rd improve & 1/3rd remain unchanged , 1/3rd worsens. Worsening most common in 1st pregnancy , 1st trimester, most common in 3rd trimester & post partum exacerbation in subsequent pregnancies. IV AchE inhibitors contraindicated – as produce uterine contraction . No contraindication to steroids reported. Uterus escapes being made up of smooth muscles – so no obstetric complication in delivery. Myasthenic weakness noticed in 2nd stage of labour when voluntary striated muscles are used. Regional anaesthesia used for Caesarean. Decreased fetal movement indicates ‘Intrauterine myasthenia’. Infant may have ‘Arthrogryposis multiplex congenita’
2. Myasthenic crisis
When associated with respiratory paralysis. Requires urgent respiratory support, ICU management (with antibiotics , fluids, AchE Therapy, plasmapheresis, IV Ig). Precipitated by infection , surgery, rapid tapering of immunosupresants. Indication of Respiratory assistance - unable to maintain: Inspiratory. Force > 20 cm H2O, Tidal Volume = 4-5 ml/kg , Maximum breathing capacity 3 times tidal vol.

3. Penicillamine induced MG
Seen in patient of RA, Wilson’s Disease, Cystinuria under D. Penicillamine. Restricted to ocular muscles. Symptoms remit after 1year stoppage of drug. Symptoms relieved by AchE inhibitors
PROGNOSIS
Untreated MG = 10 years mortality in 30 – 40%. Most patients lead normal life with life long immunosupressants. MG+thymoma in older age patients – poor prognosis (5 year survival in 30% cases)
CONCLUSION
Improved understanding of ‘AChR’ structure. Ab. Response in SNMG – better explained. Increased diagnostic sensitivity obtained using ‘Anti AChR ‘E’ subunit specific abs instead of ‘AchR’. Photopheresis with blood lymphocytes exposed to UV radiation – have a prolonged remission. Mycophenolate occupies important place in treatment field with greater safety. CT guided percutaneous ethanol injection to thymoma – shown effective, minimally invasive & safe in treatment of MG. Modern treatment is highly successful & mortality of treated disease is ‘O’ but the goal of elimination of autoimmune response to ‘AchR’ specifically without otherwise interfering with immune system is yet to be achieved.
CLINICAL FOCUS
MG is the commonest autoimmune disorder of NMJ characterized by weakness and fatiguability of voluntary muscles. Higher incidence in women and above 40 years, It is classified according to age, presence of AChR antibodies, severity and etiology. The fundamental defect is decreased AChR at PSM , reduced SF, leading to decline of muscle power of RNS, flattened postsynaptic fold and production of small EPP, shortening of synaptic fold and widening of synaptic cleft. AChR antibodies detected in 80% -90% cases. Ocular muscles are commonly involved producing ptosis and diplopia. Bulbar involvement produce dysarthria, dysphagia difficulty in mastication and deglutition and MYSHY VOICE . Facial involvement produces typical Myasthenic face, with associated day to day difficulties. DTJ are preserved. Muscle atrophy is rare. Sensory systems are not effected. Diagnosis depends on clinical examination, Pharmacological, Serological and Electrophysiological tests. There may be some associated autoimmune disorders. Modern treatment modalities are effective with ‘0’ mortality.
REFERENCE :
1. Clinical Neuro-ophthalmology , Vol – 1.
2. Clinical Care Neurology, 2nd Edition , ELCO F.M. WIJDICKS.
3. Neurology in Clinical Practice , Vol 2, 2nd Edition, Bradley
4. API Text Book of Medicine , 7th Edition
5. Web Sites: Pubmed & Googly.com
. Myasthenia gravis Article by Aashit K. Sah, MD, Aug, 2 , 2004
.Update on myasthemia Gravis by Tanvi & Co , Postgraduate Medical Journal (950)690.
. Myasthenia Gravis & Summary by James F Howard, Jr. MD.


Category (General Medicine)  |   Views (35548)  |  User Rating
Rate It


Jul21
IRRITABLE BOWEL SYNDROME
INTRODUCTION

The commonest GI disorder at present is Irritable Bowel Syndrome(IBS). Though first diagnosed 2 centuries ago IBS still remains poorly understood by physicians and patients around the World. With the availability of better technique to study GI motility and visceral functions along with the development of newer concept on importance of brain in regulating gut function significant progress has been made for better understanding of IBS. Here the current knowledge of IBS reviewed.

DEFINITION
Functional bowel disorder like IBS is defined as chronic , recurrent GI tract disorder without any organic or structural lesion . Various studies have tried to define IBS. Manning criteria (1978), Rome I criteria (1989), Rome II criteria (1998) were few studies to define IBS. The more acceptable definition is Rome II criteria.
Rome II Criteria for diagnosis of IBS
At least 12 weeks, which need not be consecutive in the preceding 12 months of abdominal discomfort or pain that has 2 of the following 3 features
1. Relieved by defecation
2. Onset associated with change in stool frequency
3. Onset associated with changes in stool pain

PREVALENCE AND EPIDEMIOLOGY
Prevalent Worldwide affecting 4% to 35% adults, common in woman than man. Woman make up 80% of population with severe IBS. In most patients the symptoms starts in late teenage or early 20s, (3rd and 4th decade) and decreases in 6th and 7th decades. After 60 years diagnosis of IBS is to be differentiated from other diseases like colon cancer and diverticulitis.
PATHOPHYSIOLOGY
A connection between brain and gut was proposed by Almy and Mullin by observing colonic motility changes related to stressful information. IBS is a complex disorder in which various physiologic process are involved , like abnormalities of intestinal motility, alteration of visceral sensory function , changes in CNS processing of sensory information’s, psychological stress and luminal factors. Interplay between gut and CNS has been called as Brain –Gut axis.


1. Altered gut motility motor activity
In IBS patients antroduodenal manometry study shows discrete clustered contraction of small intestine. These are bursts of rhythmic contractions and associated with abdominal pain. In other very prolonged contractions are seen within colon or small intestine or very high amplitude propagating contractions within the colon, more in postprandial period with episodic abdominal pain. Alteration of migratory motor complex may either delay (constipation ) or accelerate (diarrhoea) intestinal transit . It reflects the exaggeration of normal GI motility pattern. The motility pattern differs in different patients. Colonic myoelectrical & motor activity studies shows abnormalities under stressful conditions in IBS. They may exhibit increased rectosigmoid motor activity upto 3 hours after eating. Provocative stimuli like inflation of rectal balloon may lead to distention evoked contractile activity. Recording from transverse descending , sigmoid colon show high amplitude of motility index and peak amplitude in diarrhea prone IBS.
2. Enhanced Visceral Sensitivity:
Abdominal pain is a critical part of the criteria, the cause of which is not yet established. It has been demonstrated that there occurs an increased sensitivity to pain within GI tract (by balloon inflation study at various level in GI tract).Exhibit exaggerated sensory response to visceral stimuli, postprandial pain is related to entry of food to caecum in 74%. The visceral hyperalgesia appears to be selective for mechano-receptor activated stimuli as perception of intestinal mucosal electrical stimulation is normal in IBS.
Lipids lower the threshold for the first sensation of gas, discomfort and pain in IBS. The area of referred pain after lipid ingestion is increased. So postprandial symptoms are explained by a nutrient dependant exaggerated sensory components of gastrocolonic response. IBS patients don’t exhibit increased hypersensitivity anywhere in body. So disturbance is selective to visceral innervations rather than somatic.
The increased response may be due to (a) Increased endorgan sensitivity with recruitment of silent nociceptors. (b) Spinal hyperexcitability with activation nitric oxide and other neurotransmitters.(c) Endogeneous (cortical and brain stem) modulation of caudad nociceptive transmission.Development of long term hyperalgesia due to neuroplasticity resulting in permanent or semipermanent changes in neural response to chronic or recurrent visceral stimulation.
3. Influence of CNS
• In patients of IBS sensory processing is altered outside GI tract. It has proved by various studies.
a. Positron emission tomography scanning of CNS during ballon distention in IBS patients showed increased activity in prefrontal area associated with anxiety , hypervigilence and reduced activity in anterior cingulate cortex an area important for opioid binding. IBS patients exhibit no increased blood flow in the anterior cingulate gyrus but show activation of the prefrontal cortex in response to rectal activation or rectal distention. Activation of frontal lobe may activate a vigilance network and alertness. The anterior cingulate cortex and prefrontal cortex have a reciprocal inhibitory effect. Thus in IBS the preferential activation of prefrontal lobe without activation of anterior cingulate cortex may represent a form of cerebral dysfunction leading to increased visceral pain perception.
b. Functional MRI also showed different CNS activity in IBS patients.
• These studies suggest that IBS patients may process sensory information from GI tract differently than non IBS. Besides other, stimuli like stress, anxiety, depression may modulate sensory processing and influence the perception of pain.
4. Other factors
(a) Infection – Infectious gastroenteritis may increase the like hood of IBS in later life. The mechanism of post infectious IBS may be due to (i) Transient or permanent damage of enteric nervous system, the intrinsic nerve supply responsible for coordinating GI peristalsis. (ii) Development of immune hypersensitivity in which repeated exposure to benign substance induces inflammation and altered motility. (iii) Infectious agent initiates a cycle of chronic mucosal inflammation leading to altered gut motility.
Common in women and younger patients. Microbes involved are Campylobacter, Salmonella, Shigella Increased rectal endocrine cells, T – Lymphocytes and gut permeability are acute changes following Campylobacter which contributes to post infective IBS.
(b)Role of physical and sexual abuse
Several studies have shown higher incidence in physical and sexual abuse cases specially in woman. Forms of sexual abuse includes verbal aggression, exhibitionism, sexual harassment, sexual touching, rape. The pathophysiology is unknown and pain threshold is not lowered.
(c) Psychiatric factor
Recorded in 80% cases of IBS. No single psychiatrics diagnosis associated. Most patient demonstrate exaggerated symptoms . Influences pain threshold, stress alters sensory threshold.
(d) Hormonal
Serotonin (5HT) containing enterochromaffin cells in the colon and postprandial plasma 5HT are increased in Diarrhoea predominant IBS. As 5 HT plays important role in GI motility they are responsible for pathogenesis and treatment by 5 HT antagonist.

DIAGNOSIS
With a through interview and physical examination IBS can be diagnosed at the first visit. Physicians should not down play the symptoms on the ground that they exist in patients mind. Because physiologically and therapeutically definite GI motility and visceral sensation abnormalities exist in IBS patients. The accuracy of diagnosis may be 97% by proper evaluation of symptoms , normal physical examination and normal simple laboratory test. Diagnosis on basis if Rome II criteria in practically less useful for its restrictive nature. Currently American College of Gastroenterology recommends the broad definition for clinicians- Abdominal pain or discomfort associated with altered bowel habit and absence of warning signs or “red flags” suggestive of organic disease.
SYMPTOMS
The pattern of symptoms (abdominal pain , altered bowel habit) varies from person to person but remain consistent in same individual varying in intensity and frequency. Typically symptoms are intermittent with symptom-free period lasting for days , weeks or months. Rarely patients have daily symptoms.
A. Abdominal pain
Hallmark of IBS. Duration – for at least 12 weeks during preceding 12 months (need not be consecutive) or more than 25% of time during preceding 3 months. Related to defecations anyway . Intensity quality – Varies among patients but remains stable for individual patients. Described as crampy or sharp or burning May be episodic with a background of consistent for individual. Location:Hypogastium (25%), right side (20%), left side (20%) and epigastrium (10%) . Pain may be mild to be ignored or interfere daily activities. Malnutrition due to inadequate coloric intake is rare. Sleep deprivation is rare as it occurs in day and waking hours. In severe IBS may be associated nocturnal pain with poor prognosis. Pain often exacerbated by food or stress and relieved by passage of stool or flatus. Females have worsening of symptoms during premenstrual and menstrual cycle.
B. Bowel habit
Normal bowel movement ranges from 3 per week to 3 per day. The altered bowel habit varies in patients but remains consistent for individual. Three patterns are observed – Diarrhoea, constipation or alternating diarrhoea and constipation (most common). Patients having diarrhoea usually have normal consistency is morning but subsequent bowel movement becomes loose associated with urgency, abdominal cramp, flatulence and sense of incomplete evacuation. Stools become more liquid associated with mucous and feeling of drained out. Small volumes of loose stool (< 200 ml). Nocturnal diarrhoea does not occur in IBS. Diarrhoea is aggravated by food or stress. May be associated with large amount of mucous. Bleeding is not usually unless associated haemorrhoid and malabsorption and weight loss do not occur. Patients with constipation complains of rocky hard stool (scybala) associated with straining and incomplete evacuation and associated mucous . Initially may be episodic eventually becomes continuous and gradually intractable to laxative treatment.
C. Fecal incontinence
Staining of undergarments occurs in 20% of IBS. More marked in cases of IBS with diarrhoea or diarrhoea alternating with constipation. May be due to repetitive relaxation of sphincter muscles with repetitive colonic spasm.
D. Bloating and abdominal distention (Gas & Flatulence)
Very common and due to increased abdominal gas or increased sensitivity of gut to normal gas. Some patients of IBS has aerophagia, and increased belching and flatulence. Though increase in gas is complained intestinal gas amount is normal. IBS has impaired transit and tolerance of intestinal gas and tendency to reflux gas from distal to proximal.
E. Other constitutional symptoms
1. Weight loss – No weight loss
(if weight loss question about warning or “Red flag “ sign)
2. Anaemia /GI bleeding /Stool occult blood – Unusual
3. Fatigue, myalgia, arthralgia, fever, chill, night sweat – rare
F. Upper GI symptoms
25 to 50% of IBS complain dyspepsia, heart burn, nausea and vomiting. Overlap between IBS and dyspepsiaoccurs . In IBS case 55 % complain dyspepsia and in dysopeptic patients 31.7% have IBS. This functional disorder may fluctuate and indicate a single , extensive G.I disorder. IBS are more prevalent in patients having noncardiac chest pain.
PHYSICAL EXAMINATION
Thorough physical examination is needed to exclude any associated disease or make a second diagnosis. Generally the physical examinations are normal. P/A examination shows some tenderness due to visceral hypersensitivity , rectal spasm and muscular contraction. Any significant mass, tenderness or bleeding warrants other causes. Suggestive features of IBS include recurrence of abdominal pain with altered bowel habit over a period of time without progressive deterioration, onset of symptoms during stress or emotional upset, without any systemic symptoms like fever, weight loss and small volume of stool without evidence of blood. On the other hand the disorder appearing first time in old age , with a progressive course from onset , persistent diarrhoea after 48 hr fast, nocturnal diarrhoea, steatorrhoea excludes IBS.
DIFFERENTIAL DIAGNOSIS
As per the triad of symptoms in IBS the list of D/D is long.
a) Quality, location , timing of pain may help for specific disease. Pain in epigastric & periumbilical – biliary tract disease, peptic ulcer, intestinal ischaemia, Ca stomach and pancrease.
Postprandial pain with nausea, bloating – gastroparesis, partial intestinal obstruction, giardia and other parasite infestation.
b) Diarrhoea – Lactase deficiency, lexative abuse, malabsorption, hyperthyroidism , inflammatory bowel disease, infectious diarrhoea.
c) Constipation – Side effects of drugs like anticholinergics , antihypertensives and antidepressants, hypothyroidism and other endocrinopathies . Acute intermittent porphyria and lead poisoning.
INVESTIGATION
The goal is to: establish early diagnosis, find co-existing and alternative diagnosis, avoid unnecessary procedures. Certain guidelines have been delineated for diagnosis evaluation. They include duration of symptoms , the change in symptoms over time , age and sex, referral status of the patient, prior diagnosis studies, family history of colorectal malignancy, psychosocial dysfunction. Laboratory features that argues against IBS are – evidence of anaemia, raised ESR, leucocytes or RBC in stool, stool volume > 200 to 300 ml/d. Although extensive tests were followed in the past but it is now recognized that no test is necessary in younger patients who meet the criteria of IBS and have normal clinical findings without ‘red flag’ signs. But in the era of medical malpractice objective tests are necessary. A complete blood count, measuring ESR and C-reactive protein level is necessary if it is recent . If constipation is predominant estimate thyroid function test . If diarrhoea predominant –stool is tested for leucocytes and subjected to culture and examine for ova or parasites. Stool should be tested for Clostridium difficile. If persistent diarrhoea-serological test to exclude Celiac disease because incidence of celiac disease is 10 times more in IBS than normal. Flexible sigmoidoscopy – in young (< 40 years) having altered bowel habit, rectal discomfort. Colonoscopy – In age above 50 years , having family history of inflammatory bowel disease, colorectal cancer or anaemia. Upper GI endoscopy, oesophagogastroduedenoscopyy, ultrasonogram may be done to rule out other causes.
TREATMENT
General Principles : primarily focused on symptomatic relief through various modalities like patient education and reassurance, diet , supportive and behavioral therapy and pharmacotherapy. Successful management requires physicians understanding and patients knowledge and confidence. Chronic nature of the disease requires prolonged cooperative endeavor on the part of physician and patient. Treatment starts at first visit of the patient when the patient develops care and confidence on physician in way of meticulous interview and thorough physical examination. Contributing factors like diet , emotional state professional and interpersonal relationship and fear and concern are to be considered. Patient is to be explained the pathophysiology, influencing factors, chronicity of the disease.
DIET
Though many patients attribute to food allergy, true food allergy is uncommon in IBS. The act of eating may precipitate bloating, gas or abdominal discomfort. Some patients may relate the symptoms to some specific diets which are to be avoided if the symptoms recur on at least 2 occasions of stopping and reintoduction of the diet. The commonest genetic disorder Lactase insufficiency may be associated with IBS. This can be established by inducing symptoms following milk drink or relief of symptoms by giving lactose free diet.
PHARMACOTHERAPY
Due to complex pathophysiology no single agent has been able to cure IBS. Treatment is targeted at relieving individual symptoms. However FDA has approved 2 drugs which relieves multiple symptoms. (a) Tegaserod – Relieves global symptoms of IBS with constipation (Pain , bloating, discomfort & constipation). (b) Alosetron – Relieves global symptoms of IBS with diarrhoea.
I. CONSTIPATION
1. For patients of mild symptoms: life style modification, change in diet, use of fibre supplement, daily fluid intake minimum 64 OZ, food with natural fibres, use bathroom at a set time are to be tried.
2. If this is effective fiber supplementation like : I) Methylcellulose, psyllium ii) Polycarbophil, coarse bran iii) Ispaghula husk are used .These products are hydrophilic agents binding water and prevent dehydration . Only three studies have been significant 1 for polycarbophil and 2 for ispaghula husk. These agents produce bloating and distention in 30% cases. Magnesium hydroxide (Tab , Liq) may be used for constipation , though does not relive abdominal pain and bloating. Long term magnesium is harmful in renal insufficiency. Recently fiber supplementation with psyllium has been shown to reduce perception of rectal distention, indicating that fiber may have a positive affect on visceral afferent function. Beneficial effect of fibers on colonic physiology suggest an effective treatment though results of various trials are variable. Most investigations report increase in stool weight, decrease in colonic transit time , improvement of constipation. A crossover comparison of different fiber preparations found that psyllium produced greater improvement in stool pattern and abdominal pain than bran. Psyllium produces less bloating and distention. Despite equivocal data regarding efficacy stool bulking agents are worth trying in IBS.
3. Medication includes (a) Lactulose (b) Polyethylene glycol (c) Prostagladin agents – misoprostol (d) Colchicine (e) Tegaserod (5HT4 agonist ).
Tegaserod - Stimulates prokinetic activity by stimulating peristalsis. In constipation tegaserod accelerates intestinal and ascending colon transit. It selectively binds to serotonin type 4 (5 HT4) receptors in the gut and directly initiates peristalsis. It relieves constipation, accelerates orocaecal transit, bloating and abdominal pain in 2/3rd patients. It is recommended as Grade A drug for relieving global symptoms. Side effects is diarrhoea and ischaemic colitis.
Table – 1
Selected medications used for constipation in Irritable Bowel Syndrome
Drug Dosing Common side effects Comments
Fiber products Coarse bran
Ispaghula husk
Methylcellulose
Polycarbophil
Psyllium 1-2tsp/d; advance as tolerated
20g/d
0.5-1 T (1-2g) qd-tid
625 mg qd-tid
3.4 g qd-tid Bloating, abdominal distention Anecdotal; few controlled trials
Osmotic agents Lactulose
Polyethylene glycol 15-30ml (10-20)qd-tid
17g/d Bloating, cramps, flatulence
5 HT4 agonist Tegaserod 6 mg bid ac for 4-6 wk; if response positive, can consider additional 4-6 wk Headache, diarrhoea Grade A recommendation by ACG; warning issued in April 2004 about potential for serious consequence of diarrhoea and a precaution for rare, ischemic colitis
Others Colchicine


Magnesium hydroxide 0.6mg/d



622-1, 244 mg qd-qid Nausea, vomiting, diarrhoea, abdominal pain

Diarrhoea, cramps
May worsen symptoms in some patients , long term safety unknown
Mild constipation only; avoid long term use in patients with renal insufficiency

II. DIARRHOEA
Peripherally acting opiate based agents are the initial therapy of choice in diarrhoea predominant IBS. Physiologically they produce increase in segmenting colonic contraction, delay in faecal transit, increase in anal pressure and decrease in rectal perception. They are most useful when taken before anticipated stressful events. The use of antidiarrhoeal should be considered as temporary management, with a final aim of gradual withdrawal of drug with substitution of high fiber diet . Medication are Diphenoxylate HCL – Atropine, Loperamide – By increasing gut transit time it allows more fluid absorption. By increasing external anal sphincter tone decreases incontinence and soiling, Tricyclic antidepressants (TCA) – in low doses decrease frequency , Calcium channel blockers – decrease motility in some cases, Deodorized tincture of opium (DTO), Alosetron – A 5 HT3 receptor antagonist.
Alosetrin : Evaluated in diarrhoea predominant IBS. Serotonin acting on 5HT3 receptor enhances the sensitivity of afferent neurons projecting from gut. Alosetron , the drug reduces painful visceral sensation, induces rectal relaxation , increases rectal compliance, delay colonic transit time, improves stool frequency, consistency and urgency. Women respond better than man. However due to sideeffect like ischaemic colitis the drug has been withdrawn. Newer 5HT3 receptor antagonist Cilansetron have same effect as alosetron, but needs further follow up trial.

Table – 2
Selected medications used for Diarrhoea in Irritable Bowel Syndrome
Drug Dosing Common side effects Comments
Antidiarrheals Diphenoxylate
HCL –atropine

Leperamide 5 mg tid-qid


2-4 mg qid, up to 16mg/d • Bloating constipation, loss of appetite , abdominal pain, nausea, vomiting
• Abdominal pain and distention, constipation , dry mouth, nausea, vomiting Discontinue as soon as diarrhoea is controlled
Resin-binding agent Cholestyramine 4 g qd-bid Constipation , flatulence , can decrease absorption of other drugs
Opioid DTO 0.6ml qid , upto 2.4 ml/d Sedation , constipation Do not confuse with paregoric – DTO contains 25 mins more morphine than paregoric
5HT3 antagonist Alosetron 1 mg qd for 4 wk; if tolerated can be increased t 1 mg bid Constipation Grade A recommendation by ACG; discontinue immediately if constipation or signs of ischemic colitis develop; limited use program , efficacy not established in men.
Others TCAs: amoxapine
amitriptyline
alomipramine
desipramine
doxepin, imipramine
nortriptyline, protriptyline
trimipramine Various Dry mouth, dry eyes, sedation, weight gain, cardiac arrythemias, hypotension , constipation Small studies have shown reduction of abdominal pain

III. ABDOMINAL PAIN
a) Smooth muscle antispasmodic agents though used with dubious beneficial effect they are useful when pain is associated with meal and who have tenesmus. The anticholinergic drugs are to be taken 30 to 60 minutes prior to food. A metaanalysis of 26 double blind trials of antispasmodics in IBS reported better global improvement (62%), reduction in abdominal pain (64%). They are most effective when given in anticipation of pain .
b) Several TCA (amitriptyline, nortryptiline, desipramine) Though effective but side effects limit their use. Antidepressant drugs – Besides mood elevating effects, they have some physiological effect. In diarrhoea predominant IBS, imipramine slows jejunal migrating motor complex propagation and delay orocecal and whole gut transit indicating motor inhibitory effect. Tricyclic agents alter visceral afferent neural function. In another trial desipramine has shown improvement of abdominal pain (86%), improvement in stool frequency. The effect is better in diarrhoea predominant IBS than constipation. The beneficial effects of TCA on IBS is independent of anti-depression action.
c) Selective serotonin reuptake inhibitors (SSRI) may relieve pain . The efficacy of other classes of antidepressants in IBS is less evaluated. The SSRI –paroxetine accelerates orocecal transit may be useful in constipation. Citalopram blunts perception of rectal distention and reduces pain.
d) Analgesics are to be avoided . If indicated should be prescribed at low dose. Nacrotics should not be prescribed.
e) Tegaserod – relieves global symptoms including abdominal pain .

Table – 3
Selected medications used for pain in Irritable Bowel Syndrome
Drug Dosing Common side effects Comments
Anticholinergic agents Glycopyrrolate 1 mg tid Fatigue, dry mouth , constipation, urinary retention
Antismasmodic agents Dicyclomine HCI Start with 10mg qid; can increase to 40 mg qid Dry mouth , dry eyes mild sedation, urinary retention High incidence of side effects at this dose; tachycardia and orthostatic hypotension occur uncommonly
Others Acetaminophen 325mg q4-6h prn; 4,000 mg/d maximum Liver injury used at high doses, especially if taken in combination with alcohol Included in this table because commonly used OTC, but generally not effective; no controlled trials
Carbamazepine 100mg bid day 1; can increase by up to 100 mg bid prn, 1,200 mg/d maximum Anorexia, drowsiness, nausea, elevated gepatic enzymes Black box warning for aplastic anemia and agranulocytosis
Gabapentin 300 mg/d; can titrate t0 1800 mg/d in divided doses Dizziness, somnolence peripheral edema
SSRIs: Citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline Various Sedation, fatigue, sexual dysfunction , weight gain Efficacy in IBS not established; published are conflicting
Tramadol After titration , 50 mg q4-6h prn; 400 mg/d maximum Dizziness, nausea, constipation, headache, somnolence Possible addicition potential
TCAs Various Dry mouth, dry eyes,sedation, weight gain, cardiac arrythmias , hypotension Small trials , abdominal pain may be relieved

IV. BLOATING (ANTIFLATULENCE THERAPY)
Most difficult symptoms to treat, Most medications are not fully effective, Simethicone and activated charcoal provide relief in some case, Tegaserod is effective, If there is aerophagia advise to eat slowly, avoid chewing gum or drinking carbonated beverages, artificial sweetner , legumes and cabbages.

Table – 4
Selected medications used for bloating in Irritable Bowel Syndrome
Drug Dosing Common side effects Comments
Antispasmodic agent Clidinium 2.5 – 5 mg tid-qid ac ,hs Fatigue No controlled trials, off label use
Dicyclomine HCI Start with 20 mg qid; can increase to 40 mg qid Dry mouth, dry eyes, mild sedation , urinary retention High incidence of side effects at this dose; tachycardia and orthostatic hypotension occur uncommonly
Hyoscyamine 0.125 – 0.25 mg tid – qid or 0.375 – 0.75 mg SR bid Dry mouth, dry eyes , fatigue, urinary retention
Phenobarbital hyoscyamine-atropine-scoplamine 1-2 tablets bid-qid Fatigue,sedation, blurry vision
Antiflatulence Simethicone 2.4 125 mg tablets ac Safe; rare side effects; efficacy not established
Charcoal 1-2 125 mg tablets ac and hs Altered absorption of other medications , discoloration of stool Efficacy not established
5HT4 agonist
Tegaserod 6 mg bid ac for 4-6 wk; if response, can consider additional 4-6 wk Headache, diarrhea Grade A recommendation by ACG, safety and efficacy not established in men.

V. PSYCHOLOGICAL TREATMENT
Recognize if anxiety , depression , panic disorder or somatic disorder. Psychological evaluation and management at physician level without referring to psychiatrist for better patient compliance. The treatment is usually a multifocal approach including patients awareness through counseling, cognitive behavioral therapy, stress management , use of drugs to treat associated or underlying psychological disorder.
VII. ALTERNATIVE MEDICINES
Some use peppermint oil to minimize pain and bloating, Some use acupuncture and hypnotherapy , Many resort to natural and herbal therapy.
The treatment strategy of IBS depends on the severity of disorder.
Table Severity of IBS
Clinical features Mild Moderate Severe
Prevalence
Correlation without physiology
Symptoms constant
Psychosocial difficulties 70% 25% 5%
+++ ++ +
0 + +++
0 + +++
Health care issues + ++ +++
Practice type Primary Specialty Referral
In mild cases the treatment involves education , reassurance , dietary /lifestyle modification. In moderate cases the treatment includes gut acting pharmacological agents like antispasmodic, antidiarrhoeal, fiber supplements and gut serotonin modulators. In severe and refractory cases are best managed with antidepressants and other psychological treatment.
CONCLUSION
In most cases IBS is a chronic disorder in which relatively symptom free period alternate with exacerbation of symptoms. In 75% of cases the symptoms persists for 5 years.
The diagnosis of IBS should be based on Rome II criteria along with through history , physical examination . Extensive and expansive tests are not required. The treatment should be early and symptomatic. The standard therapy does not always relieve global symptoms. The medications targeting serotonin system usually relieve symptoms of constipation (Tegaserod ) or diarrhoea (Alosetron).

CLINICAL FOCUS

• IBS is commonest GI disorder but poorly understood by physicians and patients.
• This functional disorder is best defined by Rome II criteria.
• Common in young females.
• Altered gut motility motor activity and enhanced visceral sensitivity along with CNS influence are responsible for the clinical features.
• Abdominal pain, altered bowel habit and bloating are triad of symptom.
• Physical examination reveals no finding.
• Laboratory diagnostic procedures are done to exclude other diseases.
• The treatment is primarily symptomatic with more stress on diet, psychological factor, life style modification and educating the patients.
• Various medication though used for symptomatic relief few are practically used. Only two drugs targeting serotonin system relieve symptoms a) Tegaserod (constipation predominant IBS), b) Alosetron (diarrhoea predominant IBS).
• IBS is still a challenging psychosomatic disorder for physicians and patient.

REFERENCE

1. Blueno L et al : Mediators of pharmacology of Visceral sensitivity: from basic to clinical investigation ; Gastroentrology 112: 1714, 1997.
2. Talley NJ : Evaluation of drug treatment for IBS : Br J Cli Pharmacol 56: 362, 2003.
3. Mertz H : IBS – N. EJM – 349: 2136, 2003.
4. Harrison’s Principles of Internal Medicine, 16th Edn, Vol II, Page 1789- 1793.


Category (General Medicine)  |   Views (33944)  |  User Rating
Rate It


Jul21
RECENT ADVANCE IN THE MANAGEMENT OF CHRONIC HEPATITIS B INFECTION
Though the existence of a potentially transmitted form of hepatitis was documented by Lurman in 1885 the term hepatitis A & hepatitis B were introduced by Mac calluman in 1947 to categorize infectious & serum hepatitis. By 1968 other investigators notably Pince, Okochi & Murakami had established that Australia Antigen (Hbs Ag) was found specifically in serum of hepatitis B patients. In 1970 Dane et al, detected the complete hepatitis B Virion, a 42 nm double shelled particle (Dane particle). After that various researchers and epidemiological study undergone for this particle till date & it was found that an estimated 350 million people world wide and around 43 million in India carry this pathogen that can lead to cirrhosis and hepatocellular carcinoma. Management of hepatitis B and its complication requires significant knowledge of pharmacotherapeutic option which are evolving rapidly . To date 3 drugs have been approved for treatment of chronic hepatitis B that are Injectable interferon &#61537; and oral agents like lamivudine and adefovir dipivoxil. Various new drugs and immunologic modulators hold promise for treatment of chronic HBV infection and are various stages of development.


Category (General Medicine)  |   Views (33684)  |  User Rating
Rate It


Jul21
DIABETIC NEUROPATHY
INTRODUCTION:

Diabetic neuropathy is commonest complication of DM with varied clinical presentation and significant morbidity. The aetiopathogenesis, treatment and relation with glycemic control is always controversial and challenge to physicians. Various new treatment protocols are on trial.

It was described by Rollo about 200 years ago. In 1864 Michael de Calvi proposed that neuropathy is due to Diabetes. In 1945 Rundles first gave the comprehensive description.

There are 3 proposed stages of neuropathy giving emphasis on early diagnosis and treatment. They are a) Functional neuropathy- reversible biochemical alteration in nerves b) Structural neuropathy – structural damage to nerve cells but reversible c) Nerve death - Irreversible.

PHYSIOLOGY & METABOLISM OF NERVE CELLS

Normally the production and utilization of energy depending on the rate of production and utilization of adenosine triphsophate (ATP) is a balanced state in the cells. Whenever the ATP production is restricted the cells adopt by either decreasing energy requirement for biological activities, increasing glycolysis for ATP production or using phosphocreatine stores for ATP production.

Endoneurium glucose is the major substrate for energy production in peripheral nerves, which is independent of Insulin. In ischemic conditions there is reduced oxygen supply, glucose supply for glycolysis and ATP production resulting in lactate accumulation and acidosis which effects the structure and function of neuronal tissues.

AETIOPATHOGENESIS
The mechanism of multifactorial. They are vascular and metabolic. The various factors responsible are hyperglycemia, increased polyol pathway activity, myoinositol depletion, Na/K ATpase activity, endoneural hypoxia due to micro vascular disease and vasonervorum involvement.

Metabolic Theory:
a. Polyol Pathway: Normally 1% glucose is metabolized through this which is independent of insulin. Hyperglycemia leads to intracellular glucose accumulation which is converted to sorbitol by enzyme aldose reductase. Some sorbitol is fructose by sorbitol dehydrogenase. Sorbitol and Fructose damage the Schwann cell by more osmolarity and effect nerve conduction.
b. Myoinositol Pathway: Myoinositol, a cyclic hexitol is normally found in plasma and mammalian cells and major constituent of phospholipids and cell membrane. Higher levels are found in peripheral nerve. The tissue level is maintained by synthesis from glucose 6-phosphate and recovery from phosphinositol hydrolysis.
Increased polyol activity leads to depletion of myoinositol concetration by unknown mechanism, which inhibits Na+/K+ ATPase activity leading to reduced myoinosital uptake.
c. Lipids – Myelin synthesis is reduced due to reduction of membrane cholesterol, cerebroside, sphingomyelin and phosphatidyl serine – phosphatidyl inositol.

Vascular Theory:
Chronic hypoxia causing structural damage to nerves is due to reduced endoneural blood flow. In diabetes the normal vascular autoregulations is lost. Endoneural hypoxia with reduced Na+/ K+ ATpase reduce nerve conduction velocity and cause axonal atrophy. In diabetes there is multifocal loss of proximal fibres and diffuse loss of distal fibre. However both metabolic and vascular mechanisms are overlapped. Changes occur in endoneuroal and perineural blood vessels in the form of endothelial proliferation with luminal narrowing, pericyte basement membrane hyperplasia, perivascular space thickening and closed capillaries.

In general metabolic, vascular factors along with glycosylation of protein, hyperaggregation of platelets and altered haematology combindly responsible for neuropathy. Hyperglycaemia reduce pain threshold. Increased blood flow to extremities with hyperglycaemia, loss of vascular tone produce pain.

PATHOLOGY:
Peripheral nerve is classified as motor, sensory, autonomic and small or large and degree of lyelination and each with a distinct function.

Both large and small fibres are involved and on biopsy show axonal degeneration, segmental demyelination, intraneural vascular thrombi, loss of myelin due to Schwann cell damage.

ELECTROPHYSIOLOGICAL CHANGES:
The nerve conuction are more helpful than clinical and histological studies. In majority cases – axonopathy – reduced evoked motor response and sensory action potential with preservation of conduction velocity. Focal nerve entrapments: Carpal tunnel, cubital tunnel, common peroneal tunnel etc., Presence of mononeuropathy simplex/multiplex are detected.
Newer techniques like: Motor unit counting, near nerve action potential and refractory period, Needle electromyography – (recent, sophisticated), Sensory action potential and autonomic function test are sensitive.

Sequential EMG changes ranging from reduced recruitment of motor unit potentials, presence of fibrillation potential, polyphasic high amplitude long duration motor unit potential, absent of F waves occur at various stages of axonal damage.

CLINICAL CLASSIFICATION:
On the basis of clinical presentation the arbitrary classification for better understanding is accepted.
1. Gradual onset type: Distal symmetrical polyneuropathy: Usually mixed or Predominantly sensory with autonomic neuropathy
2. Acute onset type: Painful symmetric polyneuropathy, Diabetic amyotrophy (plexopathy), Mononeuropathies (Cranial, truncal, isolated, multiple mononeuropathies)., Radiculopathies, Neuropathic cachexia,
3. Autonomic neuropathy are Sympathetic and Parasympathetic

CLINICAL JUDGEMENT OF SEVERITY

By using UK screening test the severity can be graded.
Part – 1
&#61591; What is the sensation felt? – burning numbness or tingling in the feet (2 points) fatigue, cramping or arching (1 point). Maximum is 2 points.
&#61591; What is the location of symptoms? Feet (2 points) calves (1 Point): elsewhere (no points) maximum is 2 points.
&#61591; Have the symptoms ever woken you at night? yes (1 point)
&#61591; What is the timing of symptoms? Worse at night (2 points) present day and night (1 point): Present only during the day (no point) maximum is 2 points.
&#61591; How are symptoms relieved: walking around (2 points) standing (1 points); sitting or lying or no relief (no points) maximum 2 points.
&#61591; The total symptom score can then be determined: 0 to 2 – normal, 3-4 – mild neuropathy, 5-6 – moderate neuropathy & 7-9 – severe neuropathy.

Part - 2
A similar quantitative score can be made for the physical findings:
&#61591; What is the Achilles tendon reflex? - Absent (2 points for each foot); present with reinforcement (1 point for each foot).
&#61591; What is vibration sense? Absent or reduced (1 point for each foot)
&#61591; What is pin prick sensation? – Absent or reduced (1 point for each foot)
&#61591; What is temperature sensation? ( reduced ( 1 point for each foot)
The neurologic signs score can then be determined. 0-2 normal, 3-5 mild neuropathy, 6-8 moderate neuropathy and 9-10 sever neuropathy

Peripheral neuropathy is considered to be present if there are moderate or sever signs (6 points) even in the absence of symptoms or if there are at least mild signs (3 point) in the presence of moderate symptoms ( 5 points). A neurologic sign score or 8 or more indicates that the patient’s feet are at high risk for ulceration.

CLINICAL PRESENTATION
I. GRADUAL ONSET TYPE
Distal symmetrical polyneuropathy
Commonest presentation, developing over few years, detected on routine examination by absent ankle jerk. Though all somatic nerve fibres are effected, the distal parts of limbs (feet > hands) are more effected, giving rise to typical “glove and stocking” presentation. The symptoms are often symmetrical and exacerbate at night.

The symptoms and signs vary depending on predominant small or large fibre involvement.
&#61591; Small sensory neuropathy – undetected trauma to extremities specially to feet inform of scald by hot water or ulcer, infection with minor injury. May have absent or diminished sensation (cold or numb) May present as parasthesia or dysthesias in form of “tingling” or “pin and needle” sensation in extremities. Many complain severe burning or pain described as tearing , gnawing , aching or deep seated.
&#61591; Large fibre involvement: May have loss of vibration sensation followed by touch and position sense, producing sensory ataxia, unsteady gait and positive Romberg’s sign. Involvement of afferent fibres of stretch receptors lead to loss of reflexes.
&#61591; Due to loss of touch and pain sensation there may be neuropathic arthropathy or perforating ulcer in feet , associated with diminished muscle strength and vascular dysfunction.
&#61591; Diabetic neuroarthropathy involves small joints of foot and ankle. In initial phase the foot is swollen, painless and red without fever or leucocytosis (differ from infective arthropathy). The condition resembling tabes dorsalis so called “Diabetic pseudotabes”.
&#61591; In a classical presentation neurogenic atrophy of small muscle of plantar arch leads to flat foot and chronic flexion of the metatarsophalangeal joints producing callus over metatarsal heads and ulceration. The foot is warm with palpable dorsalis pedis and intact veins. Neuropathic ulcers are seen at other contact points of feet like ill fitted shoes.
&#61591; Distal symmetric polyneuropathy may show motor involvement although masked by sensory component. In Some predominant motor involvement shows flexor and extensor of foot which may be atrophied later. Involvement of small muscles of hand and feet lead to claw hand, claw foot or pescavus deformity. Predominant motor neuropathy though rare is associated with insulinoma induced repeated hypoglycaemia.
&#61591; Distal symmetrical polyneuropathy is usually associated with autonomic neuropathy.

II. ACUTE ONSET TYPE
A. Painful symmetric polyneuropathy :
o Commonest acute onset painful neuropathy. It is very painful with nocturnal exacerbation. It tends to develops 3 weeks after stressful conditions like surgery, ketosis, infection etc., May develop after insulin initiation under rapid and repeated hypoglycemia. Seen in severe diet restriction with undernourishment. This neuropathy remains for 6-18 months and disappears.
o Motor involvement is common and severe than gradual onset type.
B. Diabetic amytrophy (Plexopathy)
o Seen in elderly diabetes of short duration. It is painful and associated with stress. Typically there is painful weakness and atrophy of pelvic girdle and thigh muscles involving ileo-psoas, quadriceps relative sparing of hip extensors and hamstrings. Occasionally the peroneal and tibial muscles are effected.
o Sensory sign and symptoms may occur like pain, paraesthesia of anterior thigh and anteromedial leg radiating to dorsum of foot or pain from sacroiliac region radiating to back . The knee jerk is absent.
o The plexopathy is usually unilateral at onset but other side is somewhat involved. Shoulder girdle plexopathy is rare.
C. Mononeuropathies:
i. Cranial nerve involvement: Isolated or multiple nerve involvement may be seen without any sign of peripheral neuropathy. The III and VI are commonly involved and IV th is rarely alone. The diplopia is acute onset with pain behind and above the affected eye ( may be due to involvement of 1st and 2nd part of Vth nerve). The pupil is spared. Symptoms resolve after 6-12 weeks. The VIIth Cranial nerve may be affected rarely where the prognosis is less favorable than III and VI cranial nerve. Other upper cranial nerves may be rarely involved while the lower cranial nerves are never effected.
ii. Isolated peripheral nerve lesion. Relatively more common. The cause may be due to vascular, trauma or entrapment to superficial nerves. Any major nerve may be involved. When several nerves are affected simultaneously it is called “mononeuritis multiplex”. The nerves commonly involved are median, ulnar, radial, femoral, sciatica and peroneal , lateral cutaneous nerve of thigh. The sign and symptoms dpends on the nerve involved. The onset is usually acute painful but rarely indiduous.
iii. Radiculopathy: Relatively uncommon but correct diagnosis is necessary for unnecessary intervention. Root involvement at different segmental levels mimic different emergency conditions like constructive chest pain, pain abdomen. The cause of involvement though not definitive , may be ischaemia. EMG of involved muscles and recovery after some period without residual damage is helpful.
iv. Diabetic neuropathic cachexia: Recognized as a separate entity, where painful , acute onset symmetrical neuropathy associated with much weightloss. The nerve involvement usually disappears within 6-12 months.

III. AUTONOMIC NEUROPATHY
Usually associated with gradual onset type. It varies from mild involvement to severe masking other presentations. But mild involvement may produce significant incapacity.
A. Cardiovascular
&#61591; Postural hypotension : Commonest manifestation when postural drop occurs more than 20 mm of Hg. In some the postural drop occurs after insulin therapy greatest effect being 1 to 3 hours after injection.
&#61591; Cardiac denervation: May show partial or complete denervation with a fixed P/R of 80/90 which does not change with stress, exercises or sleep. There also occurs adnergic supersensitivity. These two factors lead to greater incidence of coronary artery spasm, painless MI, and sudden death.
&#61591; Exercise intolerance: Besides cardiac involvement changes in the autonomic tone may prevent an adequate rerouting of the blood flow after exercise. Pre-exercise evaluation is required for diabetic before advising exercise therapy.
B. Gastrointestinal tract
&#61591; Oesophageal dysmotility: May cause dysphagia, regurgitation due to low tone of LES and sense of retrosternal fullness and discomfort.
&#61591; Gastroparesis diabeticorum – In 50% of cases of diabetes due to impaired gastric acid secretion and motility produce early satiety, anorexia, nausea, vomiting, epigastric discomfort and bloating . Usually associated with bezoars. Interference of nutrient delivery to small intestine disrupts glucose absorption and exogenous insulin administration resulting a state of apparent “brittle diabetes” state.
&#61591; Diarrhoea: Common disturbing manifestation preceded by abdominal discomfort having nocturnal frequency may have faecal incontinence. The stool is usually watery but may be steatorrhic, with a frequency of 25-30 times /day. The attack may be intermittent with interval of normality or constipation. The cause of diarrhoea may be due to hypermotility by decreased sympathetic tone, bacterial over growth, pancreatic insufficiency, diabetic sprue and bile salt malabsorption.
&#61591; Constipation is a common symptoms in some studies.
&#61591; Gastric and colonic atony and enlarged gall bladder are common.
C. Genitourinary System:
&#61591; Bladder dysfunction is common. Initially may have diminished frequency with nocturia and later there may be incontinence , over flow dribbling, residual urine leading to infection.
&#61591; Impotency in form of erectile dysfunction found in more than 50% of male. Retrograde ejaculation may be seen. Neurogenic sexual dysfunction occur in 25-30% of females. Loss of testicular sensations in few studies reported.
D. Pseudomotor function
&#61591; Sweating disturbances manifest as abnormal and bizarre pattern commonly absence of sweating over distal parts of lower limb (like distal symmetrical neuropathy) with compensatory hyperhydrosis of trunk and face. Patient shows heat intolerance and there occurs nocturnal sweating. Facial sweating during meal is rare. It is more with cheese and tyramine containing foods and starts after chewing. Starting from forehead it spreads to face , scalp, back and upper chest. Anticholinergic drugs are less helpful
E. Pupillary Changes: Pupil may be constricted and that may be Argyll – Robertson type pupil. It reflects duration of diabetes, metabolic factors and other associated complications.
F. Metabolic: Hypoglycemia associated autonomic dysfunction – As glucagons and adrenal medulla depend on functional integrity of ANS, the signs and symptoms of hypoglycemia are diminished.
G. Respiratory system: Respiratory arrest may rarely occur
H. Vasomotor: Changes like loss of skinvasomotor response, peripheral vascular changes, osteopathy and charcot’s arthropathy and dependant oedema may occur.

MANAGEMENT
The protocol consists of management of hyperglycemia , metabolic abnormality , painful neuropathy and autonomic neuropathies.
I. Treatment of hyperglycemia
By assessing the glycaemic status drugs are tried to maintain good and sustained glycaemic control. In Type 2 DM diet control and oral drugs may be enough. Insulin maybe tried as its membrane stabilizing effect. In some poorly controlled diabetes pain may be aggravated when tight sugar control is done by insulin which subside after stabilization. Stable glucose control relieves pain and slow the progress of neuropathy.
II. Treatment metabolic abnormalities:
i. Aldose reductase inhibitors (ARI) – Alrestatin and Sorbinil are two drugs.
- Alrestatin – Not used due to average side effect
- Sorbinil – In dose of 250mg/day improves peroneal, median and sensory conduction velocity in 2 months, reduction of sciatic nerve sorbitol content and restoration of myoinositol is achieved. Side effects of hypersensitivity causing fever, rash , lymphadenopathy has restricted its use.
ii. Gangliosides – Facilitates neural sprouting of regenerating nerves producing subjective and objective improvement. Myoinositol is another trial drug. Seafood and vegetables like drumstick are myoinositol rich foods.
iii. Protein kinase C inhibitors (PKC) – Its role in preventing neuropathy is under trial.
iv. Gamma linoleic Acid (GLA) – GLA , an essential fatty acid is required for arachadonic acid derivatives like prostaglandin production, helpful in diabetic neuropathy.
v. Antioxidants – Several drugs have shown good results. Alpha lipoic acid, a potent hydrophilic antioxidant improves nerve blood flow, nerve glucose uptake, myoinosital content and sensory nerve conduction velocity.
vi. Neurotrophins – A group of soluble proteins like NGF, BTNT, NT3, NT4, NT5 affecting growth , differentiation, maturation , function and survival of particular set of neurons are under trial.
vii. Mecobalamin – It is an active coenzyme form of Vit B12. It is a cofactor in the methionine synthetase which functions for methyl transfer of methionine from homocysteine. It is related to folate metabolism which is responsible for purin and pyramidines of DNA. It acts as a methyl donor for synthesis of lecithin, a component of myelin sheath. Mecobalamin is better transported than cyanocobalamin into nerve cells prompting nucleic acid regeneration and protein synthesis. It promotes axonal transport and regeneration. Mecobalamin promotes myelination (phospholipid synthesis ) and lecithin synthesis of lipid sheath and inceases meylination of neurons. In a dose of 500 gm I/M or I/V thrice in a week or orally 500 to 1000&#61549;gm/ daily in effective.
viii. Nandrolone – a nonsteroidal anabolic drug in a dose of 25 mg weekly for two months.

III. Treatment of painful neuropathy

Many drugs have been tried to relieve this painful condition with various degree of relief.
a. NSAID and Analgesics:
- Tramadol a non-narcotic centrally acting analgesic in a dose of 50 mg daily increasing by 50 mg daily to maximum 400mg/day is commonly used at bed time.
- Analgesics like propoxyphene and acetaminophen given in evening before bed reduces pain. Use of NSAID are to be carefully considered due to GI and Renal complications. They may be used as short term adjuvant therapy.
- Few cases may require opiods like oxycodone where regimen is to be considered on individual basis.
b. Antidepressants
i. Tricyclic compounds (modulate alpha receptor activity): - Though used frequently potential side effects and cardiotoxicity has limited its use.
a. Amitryptiline – Started at 25 mg bed time and increasing upto 150mg depending on response. The adverse affects are anticholinergic (constipation, dry mouth, blurring vision, tachycardia, weight gain, orthostatic hypotension) and sedation.
b. Nortryptiline – Preferable in elderly diabetic due to less anticholinergic effect.
TCA are contraindicated in arrythmias, II0 and III0 heart block , MI, liver diseases , and to be used with caution in closed angle glaucoma, BHP, Constipation, urinary retention, cardiovascular and liver diseases.TCA are to be tappered over 2-4 weeks to avoid withdrawal symptoms
c. Other TCA drugs like imipramine 50-150mg/daily , desipramine 25-150mg/daily , Mianserine 30-90mg/daily may be used.
ii. Serotonin –nonepinephrine reuptake inhibitors (SNRI)
Duloxetine
- An antidepressant has been recently used with good result.
- Dose is 60mg/day. May be given upto 120mg /day. No adjustment is required in renal dysfunction but contraindication in hepatic diseases.
- Side effect - Commonly nausea, constipation, dry mouth and fatigue are seen. As it raise BP, causes tachycardia should be used with caution in cardiovascular disorders. It may cause sexual dysfunction.
Venlafaxine
- Venlafaxine or Venlafaxine ER is effective with minimal adverse events. The dose is 75mg 225 mg daily.
c. Anticonvulsants
These drugs depress abnormal discharge and raise threshold for neuronal propagation. It is effective in more than 50% patients.
i. &#61537;2-&#61540; Ligands
Gabapentin
&#61591; This anticonvulsant is now first line drug. It decreases pain, sleep interference, positive effect on mood and quality of life.
&#61591; Dose- Start – 100mg 1st day, 200mg BID 2nd and 300mg TID on 3rd day. Then increase by 100mg every three days depending on response and side effect until a maximum of 3600 mg/daily. Dose is to be titred in Renal impairment.
&#61591; Side effects: Commonly dizziness and somnolence which subside by 10 days. Less common side effects are nystagmus, tremour, diplopia, ataxia, fatigue, weight gain.

Pregabalin
&#61591; This anticonvulsant drug is similar to Gabapentin.
&#61591; Dose – Start with 75 mg twice daily. Increase to 150mg twice daily after one week depending on response upto maximum 600mg daily. Dose is to be adjusted in renal dysfunction.
&#61591; Side effects are like Gabapentin but drowsiness is common. Its better absorption and rapid onset of action than Gabapentin makes it a better choice.
&#61591; The mechanism though unclear they may reduce excitatory neurotransmitter release by binding to a2 - &#61540; protein subunits of voltage gated calcium channels.
ii. other drugs
&#61591; Carbamazepine: (200- 800mg/daily) works by slowing the recovery rate of voltage gate Na+ channel from depolarization.
&#61591; Phynytoin though have similar effect itself produce neuropathy.
&#61591; Valporic acid increases GABA level by decreasing degradation
&#61591; Newer anticonvulsant drugs like Oxcarbamazepine, Toporamate, Tamotrigine and others are better tolerated and safe. But the choice of drugs differ in different patients.
&#61591; Lamotrigine: An anticonvulsant having antidepressant properties acts by stabilization of neural membrane through voltage-gated sodium channel and inhibition of presynaptic release of glutamate. The dose is 200 – 400 mg/daily. Side effect are nausea, epigastric pain, headache , drowsiness, dizziness.
d. Local and other therapies
&#61591; Capsaicin ointment (0.075%) may be useful in painful neuropathy. It is to be applied 3-4 times daily in bulk amount. It produces burning sensation locally which gradually diminishes. The side effects are cough, sneezing, irritation and rash.
&#61591; Isosorbide dinitrate spray – Local spray before bedtime reduces pain and burning. Glyceryl nitrate patch is an alternate. The mechanism is not known.
&#61591; Several local anaesthetic cream though tried no consistent benefits achieved. Example – Lidocaine patch (5%).
&#61591; Lignocaine intravenous infusion or normal saline infusion for 6-7 days have been tried.
&#61591; Acupuncture – With minimal risk some analgesic efficacy is seen. It relieves pain and reduce analgesic need.
&#61591; Other trial drugs: Bupropion – 150- 300mg/daily, Citalopam – 40mg/daily, Methadone – 10-20mg/daily, Dextromethorphan – 400mg/daily, Paroxetine –40 mg/daily, Topiramate – 400mg/daily have been used.
&#61591; Other modalities – No good result achieved. Transcutaneous electrical nerve stimulation or magnetic insole spinal cord stimulation and frequency modulated electromagnetic stimulation
IV. Treatment of autonomic neuropathy
A. Postural hypotension
&#61591; Supportive garments like elastic stocking causing increased venous return. Gradual assumption of upright posture after getting up.
&#61591; Drugs like plasma and ECF expanders may be tried.
- High sodium intake
- Fludrocortisone – start with 0.1mg tablet daily and increase to 0.5 mg/daily.
- Vasoconstrictors like – vasopression, Levodopa and Pindolol. Indomethacin (Increase endogenous nonadrenalin and angiotensin II). Dihydroergotamine have been tried.
- Midodrine – Peripherally acting selective &#61537; agnosist in a dose of 2.5 to 10 mg thrice daily.
B. Gastroenteropathy
&#61591; Diet – small , multiple feeding with less fat and less fibres to avoid bezoars.
&#61591; Prokinetics drugs: Metoclopramide – 10mg, orally , ˝ hour before meal and bed time accelerates gastric emptying time, Domperidone – 10-20 mg 4 times daily and Mosapride are effective. Cisapride – Not used due to side effects.
&#61591; Oral erythmycin – 250mg thrice daily improves gastric emptying time.
&#61591; For diabetic diarrhoea – Loperamide , codeine , antibiotics like tetracycline, metronidazole and preprobiotics may be effective. Diphenoxylate with atropine may help.
&#61591; If medication fails jejunostomy to normal bowel may be done.
C. Bladder dysfunction
&#61591; If difficulty in initiation Credes maneuver (massage or pressure over lower abdomen above pubis) every 4 hourly to improve bladder emptying is tried. Parasympathomimetic like Bethanechol (10-30 mg thrice daily) may be helpful. Extended sphincter relaxation is achieved by &#61537;1- blocker – prazosin, doxazosin. Self catheterization maybe useful.
&#61591; Rarely bladder neck surgery is required.
D. Erectile dysfunction in males - 5 phosphodiesterase (PDE-5) inhibitors like sidenafil, tadalafil and Vardenafil are options which are rarely used due to side effect and will be obsolete soon. Papaverine injection (40-80mg) directly to corpus cavernosum may restore impotency. Penile prosthetic implants like semirigid or malleable or inflatable devices may be useful. Recently “Erect aid systems” with vaccum fitting devices has been well accepted.
E. Female sexual dysfunction – though not well studied vaginal dryness and dryspareuria respond to water based lubricants. The effect of PDE-5 may provide some benefit in absence of contraindications.
F. Hyperhydrosis – If severe anticholinergics like trihexyphenidyl or scopolamine in high doses may be used. But side effects limits their use.

SUMMARY

Diabetic neuropathy, the complication of long standing uncontrolled diabetes is common. The aetiopathogenesis is multifactorial and poorly understood. It is classified on clinical basis. The severity may be graded by UK screening test. Distal symmetrical polyneuropathy and painful symmetric polyneuropathy are common clinical presentation. Autonomic neuropathy leads to significant incapacitating situations. Sustained glycemic control and metabolic correction are first line of treatment . For painful neuropathy newer anti-depressants and anticonvulsants are quite effective. For autonomic neuropathies the treatment is supportive and symptomatic.

CONCLUSION

In the present scenario, diabetic neuropathy having multifacorial, aetiology, varied clinical neurological presentation is a challenge to the patient and physicians. Various therapies to minimize the pain and other morbid situations have been tries without 100% benefit. Many drugs are on trial phase. However the basic theme is early diagnosis, sustained glycemic control for prevention of this complication.

CLINICAL FOCUS:

&#61591; Diabetic neuropathy is commonest complication with morbidity.
&#61591; Various metabolic alterations and vascular changes lead to functional and structural damage to nerves.
&#61591; Distal symmetrical polyneuropathy and acute painful symmetric polyneuropathy are commonest among the presentations.
&#61591; The severity is graded by UK screening test.
&#61591; Silent MI and sudden death is common in diabetic autonomic neuropathy .
&#61591; Gastrointestinal and genitourinary , other autonomic complications lead to much physical and mental stress.
&#61591; Erectile dysfunction in male and inpotency is a major social problem.
&#61591; Persistent glycemic control and metabolic management are basic management.
&#61591; For painful neuropathy though various drugs have been tried the newer antidepressants and anticonvulsants are effective.
&#61591; For management of autonomic neuropathy the treatment is supportive and symptomatic.


Category (General Medicine)  |   Views (5335)  |  User Rating
Rate It


Jul21
LYMPHATIC FILARIASIS - A COMMON TROPICAL DISEASE
Filarial worms are nematodes that remain in subcutaneous tissues and lymphatics. Eight species infect human of which 4 are responsible for serious filarial infection. They are W. bancrofti, B. malayi, O.volvulus, L. loa. About 170 millions are infected world wide, transmitted by specific mosquitoes or arthropodes, a complex life cycle of larva in insects and adult worm in humans. The adult worms produce microfilaria which vary in size (200 – 250 &#61549;m long and
5-7 &#61549;m wide), may have loose sheath, when ingested by insect develop in 1-2 weeks. Adult worm survives for many years but microfilaria survives for 3-36 months. A rickettsia like bacteria Wolbachia has been seen intracellularly in cases of Brugia, Wuchereria, Mansonella and Onchocerca.

Infection is established by repeated exposure to infective larvae. In natives of endemic areas the presentation is chronic debilitating whereas in travelers and recent exposure it presents as acute manifestation.


Category (General Medicine)  |   Views (5150)  |  User Rating
Rate It


Jul19
PROGRESSIVE SUPRANUCLEAR PALSY – A RARE CASE REPORT
Progressive Supranuclear Palsy (PSP) or Steele- Richardson – Olszewski Syndrome is a neurodegenerative condition affecting brainstem and basal ganglia. Often misdiagnosed as Parkinson’s Disease. It is characterized by supranuclear ophthalmoplegia, pseudobulbar palsy, axial rigidity and mild dementia. Diagnosis is usually clinical and treatment is usually supportive.


Category (General Medicine)  |   Views (4855)  |  User Rating
Rate It


Jul19
OPSOCLONUS MYOCLONUS SYNDROME IN ADULT FOLLOWING MALARIA – A RARE CASE REPORT.
Opsoclonus1 is a high amplitude, arrhythmic, oscillatory conjugate movement of eye with frequent association with myoclonus that is sudden jerky muscle twitches either localized or generalized.
OMS also presents with other cerebellar malfunctions such as truncal and appendicular ataxia, scanning speech etc. OMS with falciparum malaria have been described. 2,3 We report a case of OMS in a case of mixed malaria infection. (+ve P. Falciparun and P. Vivax)


Category (General Medicine)  |   Views (4587)  |  User Rating
Rate It


Jul19
PRIMARY PERITONEAL HYDATIDOSIS – A RARE CASE REPORT
Hydatid disease is a parasitic infection caused by cystode, EG which is a tape worm causing endemic disease in many parts of world mainly in India3,4. The disease in man is caused by infection of larvae of the tape worm which reside in digestive system of dog (definitive host) after reaching the duodenum of man (intermediate host), the chitinous layer of the larvae is digested and released oncospheres pass through portal circulation, spreads to the liver, lungs and other organs and form cystic lesions3,4,5,6. The life cycle of the parasite is completed when intermediate host dies and body is consumed by definitive host.


Category (General Medicine)  |   Views (4533)  |  User Rating
Rate It


Jul19
YELLOW OLEANDER (THEVETIA PERUVIANA) POISONING PRESENTING WITH INTRAVASCULAR HEMOLYSIS AND RENAL FAILURE: A RARE CASE REPORT
Yellow oleander (Thevetia peruviana family Apocynaceae) is an ornamental plant; with yellow bell shaped flowers and is a tree native to Mediterranean (5, 13). The fruit is globular light green about 4-5 cm in diameter and contain a single nut which is triangular with a deep groove along the edge. Each nut contains five pale yellow seeds (4). Since ancient times it has been known toxic to humans. It has been used by Africans as an arrow poison, Greeks believed it to be poisonous to “all four footed beasts” (5). All parts of the plant are poisonous especially seeds, stems, and roots with highest toxin concentration occurring during the peak flowering stages (5). Various toxins, which are cardiac glycosides chemically, have been isolated; oleandrin, digitoxigenin, nerium folinerium, rosagenin, theventin A & B thevetoxin, peruvoside, ruvoside, cerberin, oleandroside, and also a bitter principle that act on the CNS and produces tetanoid convulsions(3,4,6,10,15). They have digoxin like effect by inhibiting Na+K+ ATPase pump (6,13). The highest oleandrin concentrations are found in the leaves (6). The clinical presentation usually resembles digoxin poisoning with gastrointestinal symptoms (Nausea, vomiting and mucosal erythema) and cardiovascular complications (bradydysrhythmias, sinus bradycardia with all types of AV nodal block, junctional rhythms, and sinus arrest, tachydysrhythmias, such as atrial tachycardia with block, Junctional tachycardia, Ventricular tachycardia, Ventricular fibrillation, Paroxysmal atrial tachycardia with block, Bidirectional ventricular tachycardia, ventricular fibrillation) and death (3,5,10). In addition, there may be paresthesias, weakness, hypertonia and excessive salivation and altered sensorium (3,10). The postmortem appearance shows generalized hemorrhages and signs of gastrointestinal irritation (11).


Category (General Medicine)  |   Views (4443)  |  User Rating
Rate It


Jul19
HYPOCALCAEMIA AND HYPOMAGNESAEMIA PRESENTING AS TREMOR AND INVOLUNTARY MOVEMENT – A CASE REPORT
Dyselectrolytemia (specially related to Ca++, Mg++) is a very common problem we face in our day-today practice. It can present with various symptoms and signs mimicking a major neurological disease. Clinical suspicion and prompt supplementation is required to reduce the morbidity and mortality of the patients.


Category (General Medicine)  |   Views (4262)  |  User Rating
Rate It


Browse Archive